Prototyping and Manufacturing of Customized Over-Encapsulated Polypills for Heart Failure With Reduced Ejection Fraction in a Safety-Net Health Care System
- PMID: 40169092
- PMCID: PMC12516335
- DOI: 10.1016/j.cardfail.2025.01.030
Prototyping and Manufacturing of Customized Over-Encapsulated Polypills for Heart Failure With Reduced Ejection Fraction in a Safety-Net Health Care System
Conflict of interest statement
Disclosures CD's spouse is employed by and holds stock in iRhythm Technologies. MDH (Huffman) has received travel support from the World Heart Federation and has an appointment at The George Institute for Global Health, which has a patent and license, and has received investment funding with intent to commercialize fixed-dose combination therapy through its social enterprise business, George Medicines. MDH (Huffman) and AA plan to submit patents for heart failure with reduced ejection fraction polypills. PYH has received honoraria from Gilead, Merck and Pfizer, unrelated to this study. ATS has consulted for Lexicon Pharmaceuticals and has research funding from Novartis Pharmaceuticals and Reprieve Cardiovascular unrelated to this study.
Figures

References
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources